Subscribe to RSS
Download PDF
DOI: 10.1055/s-0034-1383048
Total Saponins from Discorea nipponica Ameliorate Urate Excretion in Hyperuricemic Mice
Publication History
received 30 July 2013
revised 23 June 2014
accepted 04 August 2014
Publication Date:
23 September 2014 (online)
Abstract
Rhizoma Dioscoreae Nipponicae, from Discorea nipponica, is a widely used traditional Chinese herb. It is used to treat arthroncus, arthrodynia, and arthritis. Hyperuricemia is an important foundation of gouty arthritis. The current study was aimed at investigating whether the effects of total saponins from Rhizoma Dioscoreae Nipponicae on hyperuricemia were due to renal organic ion transporters in potassium oxonate-induced hyperuricemia mice. Hyperplasia of synovial cells prepared from Wistar rats was induced by IL-1β (1 × 104 µg/mL). MTT was used and to screen active components in the inhibition of hyperplasia by total saponins from Rhizoma Dioscoreae Nipponica, individual pure compounds, and different combinations of these compounds. Sixty Kun Ming mice were randomly divided into six groups: normal, model, allopurinol (40 mg/kg), and three total saponins groups receiving dose (600 mg/kg), middle (300 mg/kg), and low doses (60 mg/kg). Hyperuricemic mice were induced with potassium oxonate (300 mg/kg) intragastrically. The total saponins were given six days and the positive drug allopurinol was given one day before inducing hyperuricemia. The serum and urine levels of uric acid and creatinine and the fractional excretion of uric acid were measured in normal and hyperuricemic mice treated with Rhizoma Dioscoreae Nipponicae and allopurinol. The mRNA and protein levels of the mouse urate transporter 1, glucose transporter 9, organic anion transporter 1, and organic anion transporter 3 were analyzed by real-time-PCR and Western blotting methods, respectively. Total saponins from Rhizoma Dioscoreae Nipponicae could effectively reverse potassium oxonate-induced alterations in renal mouse urate transporter 1, glucose transporter 9, organic anion transporter 1, and organic anion transporter 3 mRNA and protein levels, resulting in enhancement of renal urate excretion in mice. These findings suggested that the total saponins from Rhizoma Dioscoreae Nipponicae had a uricosuric effect on the regulation of renal organic ion transporters in hyperuricemic animals.
-
References
- 1 Chen GL, Xu SY. Research progress for animal hyperuricemia model. Chin Pharmacol B 2004; 20: 369-373
- 2 Hu QH, Jiao RQ, Wang X, Lv YZ, Kong LD. Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice. J Ethnopharmacol 2010; 128: 685-692
- 3 Wang LY, Wang CJ, Yuan TD, Wang MZ, Bai HB, Yuan XD, Wang CB, Han ZW. Study of protection of aqueous extract of Arctium lappa root on hyperuricemia mice. J Ethnopharmacol 2011; 22: 4054-4055
- 4 Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32: 1737-1742
- 5 Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K. Serum uric acid: a risk factor and a target for treatment. J Am Soc Nephrol 2006; 17: 69-73
- 6 Coi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442-447
- 7 Paolo B, Caroline N, Olof N, Weimin Y. A prospective study of gout and cancer. Eur J Cancer Prev 2009; 18: 127-132
- 8 Eraly SA, Vallon V, Rieg T, Gangoiti JA, Woof WR, Siuzdak G, Barshop BA, Nigam SK. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 2008; 33: 180-192
- 9 Wang F. Research progresses of urate transporters in the kidney. Section Endocrinol Foreign Med Sci 2004; 24: 388-390
- 10 Sato M, Wakayama T, Mamada H, Shirasaka Y, Nakanishi T, Tamai I. Identification and functional characterization of uric acid transporter Urat1 (SLC22a12) in rats. Biochim Biophys Acta 2011; 1808: 1441-1447
- 11 Liu DY, Yao XT, Ni YX, Zhong J, Zhu ZM. Update of relationship between glucose transporter-like protein-9 and uric acid metabolism. Chin J Endocrinol Metab 2012; 28: 81-84
- 12 Li CQ, Zhao JJ, Wang X, Li CG, Miao ZM. Effect of VLDL on the expression of the human urate transporter gene (hOAT1) in HK-2 cells. J Shan Dong University 2008; 46: 579-585
- 13 Habu Y, Yano I, Takeuchi A, Saito H, Okuda M, Fukatsu A, Inui K. Decreased activity of basolateral organic ion transporters in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and oOCT2. Biochem Pharmacol 2003; 661: 1107-1114
- 14 Chinese Pharmacopoeia Commission. The Pharmacopoeia of the Peopleʼs Republic of China. 2010 edition. Beijing: The Chemical Industry Publishing House; 2010: 250-251
- 15 Ding XL, Li Q. Research progress of Chinese medicine of Rhizoma Dioscoreae Nipponicae. Chongqing J Res Chin Drugs Herbs 2003; 2: 55-57
- 16 Yu SY, Ji FR, Yu DH, Liu SM. Studies on chromatography fingerprint of Dioscorea nipponica serum. Chin J Exp Traditional Med Formulae 2012; 18: 80-81
- 17 Yu SY, Liu Y, Liu SM. Simultaneous determination of the contents of protodioscin, methyl protodioscin and pseudo protodioscin in Rhizoma Dioscoreae Nipponicae with RP-HPLC. Chin J Exp Traditional Med Formulae 2012; 18: 96-98
- 18 Lu F, Liu L, Yu DH, Li XZ, Zhou Q, Liu SM. Therapeutic effect of Rhizoma Dioscoreae Nipponicae on gouty arthritis based on the SDF-1/CXCR4 and p 38 mark pathway: An in vivo and in vitro study. Phytother Res 2014; 28: 280-288
- 19 Zhou Q, Zhang C, Yu DH, Liu SM. Study on uric acid reducing effect of total saponins from Rhizoma Dioscoreae Nipponicae in treating hyperuricemia and in vitro study of its anti-inflammatory effect. Chin J Traditional Chin Med Pharm 2013; 28: 1444-1448
- 20 Yao L, Liu SM. Study on the new effective ingredients of Rhizoma Dioscoreae Nipponicae on decreasing the uric acid. Chin Arch Traditional Chin Med 2010; 28: 1979-1981
- 21 Yao L, Liu SM. Study on the effective ingredients of Rhizoma Dioscoreae Nipponicae on experimental acute gouty arthritis. Chin Arch Traditional Chin Med 2010; 28: 1724-1726
- 22 Yao L, Dong W, Lu F. An improved acute gouty arthritis rat model and therapeutic effect of rhizome Dioscoreae nipponicae on acute gouty arthritis based on the protein-chip methods. Am J Chin Med 2012; 40: 121-134
- 23 Pascual E, Martinez A, Ordonez S. Gout: the mechanism of urate crystal nucleation and growth. A hypothesis based in facts. Joint Bone Spine 2013; 80: 1-4
- 24 Stamp LK, Zhu XY, Jordan S, Edwards NL, Taylor W. Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers. Semin Arthritis Rheum 2011; 40: 483-500
- 25 Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 2005; 9: 195-205
- 26 Tasic V, Hynes AM, Kitamura K, Cheong H, Lozanovski VJ, Gucev Z, Jutabha P, Anzai N, Sayer JA. Clinical and functional characterization of URAT1 variants. PloS One 2011; 6: 1-8
- 27 Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, Hosoya T. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15: 164-173
- 28 Vazquez-Mellado J, Jimenez-Vaca AL, Cuevas-Covarrubias S, Alvarado-Romano V, Pozo-Molina G, Burgos-Vargas R. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout. Rheumatology (Oxford) 2007; 46: 215-219
- 29 Wang X, Wang CP, Hu QH, Lv YZ, Zhang X, Yang ZO, Kong LD. The dual actions of Sanmiao wan as a hypouricemic agent: Down regulation of hepatic XOD and renal mURAT1 in hyperuricemia mice. J Ethnopharmacol 2010; 128: 107-115
- 30 Caulfield MJ, Munroe PB, Neill DO, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, Shaw-Hawkins S, Dobson RJ, Wallace C, Newhouse SJ, Brown M, Connell JM, Dominiczak A, Farrall M, Lathrop GM, Samani NJ, Kumari M, Marmot M, Brunner E, Chambers J, Elliott P, Kooner J, Laan M, Org E, Veldre G, Viigimaa M, Cappuccio FP, Ji C, Iacone R, Strazzullo P, Moley KH, Cheeseman C. SLC2A9 is a high-capacity urate transporter in humans. PloS Med 2008; 5: 1509-1523
- 31 Preitner F, Bonny O, Laverriere A, Rotman S, Firsov D, Costa AD, Metref S, Thorens
B. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces
hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA 2009; 106: 15501-15506
MissingFormLabel
- 32 Jia C, Wei MJ, Zhao XL. Progress in the interaction between the organ anion transport protein OAT1, OAT3 and drugs metabolism. Chin J Clin Pharmacol 2010; 26: 957-960
- 33 Yu XY, Zhou J, Tang K, Ouyang YW, Zuo AR. Effect of extraction from tea root on hyperuricemia mice. Chin J Exp Traditional Med Formulae 2012; 18: 193-195
- 34 Hua J, Huang P, Zhu CM, Yuan X, Yu CH. Anti-hyperuricemic and nephroprotective effects of Modified Simiao Decoction in hyperuricemic mice. J Ethnopharmacol 2012; 142: 248-252
- 35 Aringer M, Graessler J. Understanding deficient elimination of uric acid. Lancet 2008; 372: 1929-1930
- 36 Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion
of uric acid is present in patients with apparent high urinary uric acid output. Arthritis
Rheum 2002; 47: 610-613
MissingFormLabel